Abbott Laboratories Cuts Outlook, Says Mild Flu Season Hurt Sales
Abbott Laboratories cut its full-year earnings outlook to account for a recent acquisition and said a weaker-than-expected flu season hurt its recent quarter.
- Abbott stock slips on guidance cut, ranks 10th in healthcare equipment Quant ratings Seeking Alpha —
- Abbott forecasts 6.5%-7.5% 2026 comparable sales growth while integrating Exact Sciences with $0.20 EPS dilution Seeking Alpha —
- Abbott trims 2026 profit forecast on Exact deal hit, shares fall - Reuters Reuters —
- Abbott trims 2026 profit forecast on Exact deal hit, shares fall The Globe and Mail —
- Abbott Stock Tumbles on Earnings. Nutrition Business Is Struggling and Merger Costs Biting. Barrons —